advanced chronic kidney disease with type 2 diabetes(Phase 3)
Catalysts
— Q2 2027
— H2 2029
Status note REGEN-006 (PROACT 1) Phase 3 ongoing in Stage 4 and late Stage 3b CKD; RMAT designation; enrollment completed for the accelerated approval efficacy analysis.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.